Cleared Traditional

K100287 - JBAIDS INFLUENZA A/H5 DETECTION KIT, MODEL JRPD-ASY-0136

K100287 is an FDA 510(k) clearance for JBAIDS INFLUENZA A/H5 DETECTION KIT, manufactured by U.S. Army Medical Material Development Command. The device is a Class 2 Microbiology device with product code NXD cleared through the Traditional 510(k) pathway after a 158-day FDA review.

K100287 · U.S. Army Medical Material Development Command · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2010
Decision
158d
Days
Class 2
Risk

K100287 is an FDA 510(k) clearance for the JBAIDS INFLUENZA A/H5 DETECTION KIT, MODEL JRPD-ASY-0136. Classified as Nucleic Acid Amplification, Novel Influenza A Virus, A/h5 (asian Lineage) Rna (product code NXD), Class II - Special Controls.

Submitted by U.S. Army Medical Material Development Command (Fort Detrick, US). The FDA issued a Cleared decision on July 6, 2010 after a review of 158 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3332 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all U.S. Army Medical Material Development Command devices

FDA 510(k) Submission Details - K100287

510(k) Number K100287 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 29, 2010
Decision Date July 06, 2010
Days to Decision 158 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
56d slower than avg
Panel avg: 102d · This submission: 158d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NXD Device Classification - Class 2, Special Controls

Product Code NXD Nucleic Acid Amplification, Novel Influenza A Virus, A/h5 (asian Lineage) Rna
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3332
Definition Novel Influenza A Virus Reagents Are Used In Nucleic Acid Amplification Tests To Directly Detect And Differentiate Novel Influenza A Virus Specific Rna Gene Segments In Human Respiratory Specimens Or Viral Cultures. Detection And Differentiation Of Specific Rna Gene Segments Aids In The Diagnosis Of Influenza Caused By Novel Influenza A Viruses In Patients With Clinical And Epidemiological Risk Of Infection With These Viruses. They Also Aid In The Presumptive Identification Of Specific Novel Influenza A Viruses And Provide Epidemiological Information On Influenza. These Reagents Are Primers And Probes, Along With A Specific Novel Influenza Virus Control.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - NXD Nucleic Acid Amplification, Novel Influenza A Virus, A/h5 (asian Lineage) Rna

Devices cleared under the same product code (NXD) and FDA review panel - the closest regulatory comparables to K100287.
CDC HUMAN INFLUENZA VIRUS REAL-TIME RT- PCR DETECTION AND CHARACTERIZATION PANEL
K080570 · Centers For Disease Control and Prevention · Sep 2008
INFLUENZA A/H5 (ASIAN LINEAGE) VIRUS REAL-TIME RT-PCR PRIMER AND PROBE SET
DEN060008 · Centers For Disease Control and Prevention · Feb 2006